Get the Stockscreener App
2.17
4.82%
-0.11
After Hours:
2.14
-0.03
-1.38%
Allogene Therapeutics Inc stock is traded at $2.17, with a volume of 74.01M.
It is down -4.82% in the last 24 hours and down -9.58% over the past month.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
See More
Previous Close:
$2.28
Open:
$1.895
24h Volume:
74.01M
Relative Volume:
8.45
Market Cap:
$529.00M
Revenue:
$22,000
Net Income/Loss:
$-190.89M
P/E Ratio:
-2.4994
EPS:
-0.8682
Net Cash Flow:
$-149.63M
1W Performance:
-19.63%
1M Performance:
-9.58%
6M Performance:
+70.87%
1Y Performance:
+48.63%
1-Day Range:
$1.85
$2.175
1-Week Range:
$1.85
$4.46
52-Week Range:
$0.8621
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.17 | 555.81M | 22,000 | -190.89M | -149.63M | -0.8682 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Jefferies | Buy |
| Jan-09-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics Prices Large Common Stock Offering - TipRanks
ALLO Maintained by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? - Yahoo Finance
ALLO Stock Slumps As $175M Secondary Offering Hits Tape - timothysykes.com
ALLO Stock Slides As $175M Equity Offering Hits Tape - StocksToTrade
[8-K] Allogene Therapeutics, Inc. Reports Material Event - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) to Sell 87.5M Shares at $2.00 - Stock Titan
Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings - Benzinga
Jefferies raises Allogene stock price target to $10 on trial data By Investing.com - Investing.com South Africa
Jefferies raises Allogene stock price target to $10 on trial data - Investing.com
Allogene publishes preclinical data for autoimmune CAR T therapy - Investing.com
Autoimmune drug candidate cleared B and T cells in lupus models - Stock Titan
Allogene Therapeutics Prices $175 Million Public Offering - marketscreener.com
Allogene Therapeutics Shares Slide on Up to $201.3M Public Offering - Moomoo
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Biotech Allogene sells 87.5M shares at $2 to raise $175M - Stock Titan
ALLO Seeks Capital with a New Offering Below Previous Close - GuruFocus
Allogene prices $175 million stock offering at $2 per share By Investing.com - Investing.com South Africa
ALLO Maintained by Argus Research -- Price Target Raised to $3.8 - GuruFocus
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - Bitget
Allogene Therapeutics, Inc. Prices Public Offering of 87.5 Million Shares at $2.00 per Share - Quiver Quantitative
Allogene prices $175 million stock offering at $2 per share - Investing.com
Allogene Therapeutics announces pricing of public offering of common stock - marketscreener.com
Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock - TradingView — Track All Markets
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
ALLO Maintained by Citizens -- Price Target Raised to $8.00 - GuruFocus
ALLO Maintained by HC Wainwright & Co. -- Price Target Raised to $12 - GuruFocus
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study - TradingView — Track All Markets
ALLO Maintained by Baird -- Price Target Raised to $9.00 - GuruFocus
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
Allogene Therapeutics Stock Soars 12% On Positive Phase 2 Data For Lymphoma Treatment - TIKR.com
H.C. Wainwright raises Allogene stock price target on trial data - Investing.com UK
H.C. Wainwright raises Allogene stock price target on trial data By Investing.com - Investing.com Australia
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Bernstein raises Allogene stock price target on trial data By Investing.com - Investing.com India
Bernstein raises Allogene stock price target on trial data - Investing.com UK
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Allogene Therapeutics (ALLO) Plans $175M Stock Offering - GuruFocus
Allogene Therapeutics, Inc. Files Form 8-K Current Report with SEC on April 13, 2026 2 - Minichart
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell LymphomaSlideshow (NASDAQ:ALLO) 2026-04-14 - Seeking Alpha
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock - Bitget
Why Allogene Therapeutics (ALLO) Is Up 16.8% After Early ALPHA3 MRD Clearance Data And What's Next - simplywall.st
Allogene's off-the-shelf CAR-T strikes at residual lymphoma cells in Phase II win - FirstWord Pharma
Allogene (ALLO) Reports Positive Interim Analysis from Pivotal A - GuruFocus
Citizens raises Allogene stock price target on trial data strength By Investing.com - Investing.com Australia
Citizens raises Allogene stock price target on trial data strength - Investing.com UK
Allogene Therapeutics announces proposed public stock offering and suspends existing sales agreement - Investing.com South Africa
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel - TipRanks
Allogene Therapeutics plans $175 million stock offering By Investing.com - Investing.com India
ALLO Stock Jumps As Traders Target ALPHA3 Trial Catalyst - timothysykes.com
Allogene Therapeutics stock hits 52-week highhere's why - MSN
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):